Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum HypertensionNCT06500351
Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Postpartum. Hypertension
An observational study of Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension, run by Sohag University at 1 site in Egypt.
Trial summary
This is an observertional study aimed at Study the association between Renalase(rs10887800) Genotyping \& Leucocytes telomere length in patients with postpartum hypertension whether new onset( denovo) or persistent following pregnancy complicated by hypertension. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 25 Jun 2024to 1 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- Adult
Study population: Patients who were 18 years or above, and have a diagnosis of postpartum hypertension
Who may be able to join
- Patients who are18 years or above, and have a diagnosis of postpartum hypertension(regardless of where they received their antenatal care) attended to Sohag university hospitals
Who cannot join
- All pregnant women with medical disorders in pregnancy other than Hypertensive disorders during pregnancy (e.g., sickle cell disease, heart disease, kidney and other connective tissues disorders) will be excluded from the study. Also we excluded measurements taken during scheduled or unscheduled surgical encounters given potential for interaction with anesthetic agents
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Sohag university hosoital
Sohag
Amera Morad Foad Hamdy, Assistant Professor, +201006591449, ameramoradfoad@gmail.com
About this study
Official title: Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension.
This is an observertional study aimed at Study the association between Renalase(rs10887800) Genotyping \& Leucocytes telomere length in patients with postpartum hypertension whether new onset( denovo) or persistent following pregnancy complicated by hypertension.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| denovo postpartum hypertension | females with new onset hypertension after delivary | |
| persitant postpartum hypertension | females with preexisting hypertension or preeclampsia that persist after delivery | |
| control | females with normal postpartum blood pressure |
What is being measured
The primary outcome is the main question the study is designed to answer.
Renalase(rs10887800) Genotyping
The presence of gene polymorphism whether homogenetic or heterogenetic
Measured: 1 year
Secondary outcomes (1)
Leucocytes telomere length
Measurement of the relative length of WBCs telomere in patints with postpartum hypertension
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jul 2024
- Study start25 Jun 2024
- Primary completion25 Jun 2025 (estimated)
- Study completion1 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum HypertensionStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amera Morad Foad, Sohag University
- Investigators
- Amera Morad Foad, assistant professor, Principal investigator, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06500351
- Sponsor's protocol ID
- Soh-Med-24-06-08PD
- Status last verified
- Jul 2024
- First submitted
- 8 Jul 2024
- Last updated
- 16 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension.
- ClinicalTrials.gov ID
- NCT06500351
- Acronym / sponsor ID
- Soh-Med-24-06-08PD
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 25 Jun 2024 (actual)
- Primary completion
- 25 Jun 2025 (estimated)
- Study completion
- 1 Sep 2025 (estimated)
- First posted
- 15 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an observertional study aimed at Study the association between Renalase(rs10887800) Genotyping \& Leucocytes telomere length in patients with postpartum hypertension whether new onset( denovo) or persistent following pregnancy complicated by hypertension.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| denovo postpartum hypertension | – | –females with new onset hypertension after delivary |
| persitant postpartum hypertension | – | –females with preexisting hypertension or preeclampsia that persist after delivery |
| control | – | –females with normal postpartum blood pressure |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- Patients who were 18 years or above, and have a diagnosis of postpartum hypertension
Key inclusion criteria (1 listed)
- Patients who are18 years or above, and have a diagnosis of postpartum hypertension(regardless of where they received their antenatal care) attended to Sohag university hospitals
Key exclusion criteria (1 listed)
- All pregnant women with medical disorders in pregnancy other than Hypertensive disorders during pregnancy (e.g., sickle cell disease, heart disease, kidney and other connective tissues disorders) will be excluded from the study. Also we excluded measurements taken during scheduled or unscheduled surgical encounters given potential for interaction with anesthetic agents
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Renalase(rs10887800) Genotyping
Time frame: 1 year
The presence of gene polymorphism whether homogenetic or heterogenetic
1 secondary outcome
Leucocytes telomere length
Time frame: 1 year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2024.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Amera Morad Foad, assistant professor principal investigator
Sohag University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Renalase(rs10887800) Genotyping & Leucocytes Telomere Length in Patients With Postpartum Hypertension, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Amera Morad Foad, assistant professor (+201006591449, ameramoradfoad@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Renalase(rs10887800) Genotyping (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2024.